The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

På svenska

Author

  • Susan J Ramus
  • Antonis C Antoniou
  • Karoline B Kuchenbaecker
  • Penny Soucy
  • Jonathan Beesley
  • Xiaoqing Chen
  • Lesley McGuffog
  • Olga M Sinilnikova
  • Sue Healey
  • Daniel Barrowdale
  • Andrew Lee
  • Mads Thomassen
  • Anne-Marie Gerdes
  • Torben A Kruse
  • Uffe Birk Jensen
  • Anne-Bine Skytte
  • Maria A Caligo
  • Annelie Liljegren
  • Annika Lindblom
  • Håkan Olsson
  • Ulf Kristoffersson
  • Marie Stenmark-Askmalm
  • Beatrice Melin
  • Susan M Domchek
  • Katherine L Nathanson
  • Timothy R Rebbeck
  • Anna Jakubowska
  • Jan Lubinski
  • Katarzyna Jaworska
  • Katarzyna Durda
  • Elżbieta Złowocka
  • Jacek Gronwald
  • Tomasz Huzarski
  • Tomasz Byrski
  • Cezary Cybulski
  • Aleksandra Toloczko-Grabarek
  • Ana Osorio
  • Javier Benitez
  • Mercedes Duran
  • Maria-Isabel Tejada
  • Ute Hamann
  • Matti Rookus
  • Flora E van Leeuwen
  • Cora M Aalfs
  • Hanne E J Meijers-Heijboer
  • Christi J van Asperen
  • K E P van Roozendaal
  • Nicoline Hoogerbrugge
  • J Margriet Collée
  • Oskar Th Johannsson
Show all

Summary, in English

Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 BRCA1 and 7,132 BRCA2 carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian cancer risk in BRCA2 carriers; rs10088218 per-allele hazard ratio (HR) = 0.81 (95% CI: 0.67-0.98) P-trend = 0.033, rs2665390 HR = 1.48 (95% CI: 1.21-1.83) P-trend = 1.8 × 10(-4), rs717852 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.6 × 10(-4), rs9303542 HR = 1.16 (95% CI: 1.02-1.33) P-trend = 0.026. Two loci were associated with ovarian cancer risk in BRCA1 carriers; rs10088218 per-allele HR = 0.89 (95% CI: 0.81-0.99) P-trend = 0.029, rs2665390 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.1 × 10(-4). The HR estimates for the remaining loci were consistent with odds ratio estimates for the general population. The identification of multiple loci modifying ovarian cancer risk may be useful for counseling women with BRCA1 and BRCA2 mutations regarding their risk of ovarian cancer.

Publishing year

2012-04

Language

English

Pages

690-702

Publication/Series

Human Mutation

Volume

33

Issue

4

Document type

Journal article

Publisher

John Wiley & Sons Inc.

Topic

  • Cancer and Oncology

Keywords

  • Adult
  • BRCA1 Protein
  • BRCA2 Protein
  • Cohort Studies
  • Female
  • Genetic Predisposition to Disease
  • Heterozygote
  • Humans
  • Middle Aged
  • Mutation
  • Odds Ratio
  • Ovarian Neoplasms
  • Polymorphism, Single Nucleotide
  • Retrospective Studies

Status

Published

Research group

  • Lund Melanoma Study Group

ISBN/ISSN/Other

  • ISSN: 1059-7794